Eric Crombez - Concepedia

Author

Eric Crombez

Takeda (United States)

Also Known As

ERIC CROMBEZ, Eric A. Crombez, Eric Crombez

Publications

1.1K

Citations

H-Index

Concepts

All Affiliations

Takeda (United States)University of California, Los Angeles Shaare Zedek Medical Center University College London Lurie Children's Hospital

About

Eric Crombez is an author at Takeda (United States) specializing in medicine, pharmacology, and inherited metabolic disease.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	12	12	706
2	Health Sciences	4	4	165
3	Natural Sciences	2	2	49
4	Public Health	1	1	92
5	Allergy	1	1	19

Eric Crombez

Publications

962

Citations

H-Index

Page 1

	Year	Citations
Efficacy of Sapropterin Dihydrochloride in Increasing Phenylalanine Tolerance in Children with Phenylketonuria: A Phase III, Randomized, Double-Blind, Placebo-Controlled Study Friedrich K. Trefz, Barbara K. Burton, Nicola Longo, The Journal of Pediatrics Sapropterin DihydrochlorideMedicineInherited Metabolic DiseaseClinical NutritionPharmacology	2009	190
Safety and efficacy of 22 weeks of treatment with sapropterin dihydrochloride in patients with phenylketonuria Phillip Lee, Eileen P. Treacy, Eric Crombez, American Journal of Medical Genetics Part A Sapropterin DihydrochlorideMetabolic DisorderPharmacotherapyMetabolic SyndromeTranslational Medicine	2008	101
Expanded newborn screening identifies maternal primary carnitine deficiency Lisa A. Schimmenti, Eric Crombez, Bernd Schwahn, Molecular Genetics and Metabolism NutritionNewborn ScreeningInfant NutritionGenetic EpidemiologyPediatrics	2006	92
Enzyme replacement therapy with velaglucerase alfa in Gaucher disease: Results from a randomized, double‐blind, multinational, Phase 3 study Derlis Gonzalez, Hadhami Ben Turkia, Elena Lukina, American Journal of Hematology	2012	84
Velaglucerase alfa enzyme replacement therapy compared with imiglucerase in patients with Gaucher disease Hadhami Ben Turkia, Derlis Gonzalez, Norman W. Barton, American Journal of Hematology ImmunohematologyGaucher DiseaseEnzyme Replacement TherapyTransfusion MedicineHematology	2012	70
Safety and efficacy of velaglucerase alfa in Gaucher disease type 1 patients previously treated with imiglucerase Ari Zimran, Gregory M. Pastores, Anna Tylki‐Szymańska, American Journal of Hematology Gene Activation TechnologyAutoimmune DiseaseImmunodeficienciesInherited Metabolic DiseaseGlycobiology	2012	61
Velaglucerase alfa (VPRIV) enzyme replacement therapy in patients with Gaucher disease: Long‐term data from phase III clinical trials Derralynn Hughes, Derlis Gonzalez, Elena Lukina, American Journal of Hematology	2015	51
Clinical and Molecular Heterogeneity in Patients with the CblD Inborn Error of Cobalamin Metabolism Isabelle R. Miousse, David Watkins, David Coelho, The Journal of Pediatrics Vitamin NutritionMetabolic SyndromeCbld Inborn ErrorMetabolic DisorderMedicine	2008	48
Metachromatic Leukodystrophy Florian Eichler, Timothy M. Cox, Eric Crombez, Journal of Child Neurology	2016	43
Long-term velaglucerase alfa treatment in children with Gaucher disease type 1 naïve to enzyme replacement therapy or previously treated with imiglucerase Laurie D. Smith, William J. Rhead, Joel Charrow, Molecular Genetics and Metabolism	2015	36

Page 1